Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized, Phase II Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Mild to Moderate Atopic Dermatitis

Trial Profile

A Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized, Phase II Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Mild to Moderate Atopic Dermatitis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2019

At a glance

  • Drugs B 244 (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions
  • Sponsors AOBiome
  • Most Recent Events

    • 08 Jan 2019 Planned End Date changed from 1 Apr 2019 to 1 Jul 2019.
    • 08 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Apr 2019.
    • 08 Jan 2019 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top